High blood glucose levels, memory, and dementia risk: evidence and implications

Initial note

This article was previously published and has been updated according to scientific and divulgative criteria. The purpose is informative and does not replace medical advice. For any clinical decision, consult your doctor.

IN BRIEF

• Observational studies show associations between higher glucose levels (even in the non-diabetic range) and poorer memory performance along with structural changes in the hippocampus.
• The presence of diabetes is associated with an increased risk of dementia; hypothesized mechanisms include vascular damage, inflammation, and alterations in neuronal metabolism.
• Clinical evidence is predominantly observational: it indicates correlations but does not automatically prove direct causality.
• Public health strategies aimed at reducing metabolic risk factors at the population level (physical activity, weight control, quality diet) are plausible and consistent with current knowledge.

Abstract: what does science say?

The topic concerns the relationship between blood glucose levels (measured by fasting glycemia and HbA1c) and cognitive function, particularly memory and the risk of dementia. Numerous observational studies document that, in addition to cases of overt diabetes, persistently higher glycemic values in the non-diabetic population can also be associated with lower cognitive performance and structural changes in the hippocampus, a key region for memory. Evidence suggests that the magnitude of risk depends on scale (how high glucose is), duration (chronic exposure), and context (age, cardiovascular comorbidities, presence of obesity). However, most evidence is associative: it does not allow for asserting certain causality. Possible biological mechanisms include microvascular lesions, oxidative stress, inflammation, and altered neuronal plasticity. Unresolved elements remain, for example, whether reducing glycemic levels in the non-diabetic population produces measurable long-term benefits on dementia; targeted clinical trials and studies with biomarker measurements are needed to answer this.

What is meant by glycemia and HbA1c

Fasting glycemia measures blood sugar at a specific moment; HbA1c reflects the average glycemia over the last 2–3 months. Both are used clinically: glycemia for diagnosis and immediate control, HbA1c as an indicator of prolonged glycolytic exposure. For this reason, HbA1c is often used in studies evaluating the effect of chronic exposure on the brain. It should be remembered that values within the defined "normal" range can still show variation and that the relationship with cognitive outcome may be non-linear and influenced by other factors (age, weight, smoking, cardiovascular comorbidities).

What the evidence shows, in summary

Population research and non-experimental clinical studies show consistent associations: higher glucose and HbA1c levels are correlated with faster cognitive decline and a higher risk of dementia in the adult population. Imaging studies detect reductions in volume and microstructural alterations in the hippocampus associated with higher glycemic levels. On the other hand, the presence of diabetes remains a consolidated risk factor for dementia, particularly for forms with a vascular component, while the exact mechanisms linking metabolism and neurodegenerative pathology are the subject of continuous scientific investigation.

What it means in practice

For the reader: the results do not suggest that simply lowering blood sugar guarantees the prevention of dementia, but they reinforce the concept that metabolic health is an integral part of brain health. In daily practice, maintaining a lifestyle that reduces cardiometabolic factors (regular physical activity, healthy body weight, a diet rich in fiber, vegetables, and whole foods, limiting sugary drinks and dietary excesses) is a strategy consistent with public health recommendations and with evidence associating better glycemic control with better cognitive outcomes in some observational studies [2][3][4].

For people already diagnosed with diabetes: glycemic control remains an important component of clinical management to reduce vascular complications and potentially limit cognitive risk. However, it is important to avoid strategies that may increase the risk of hypoglycemia, as episodes of severe hypoglycemia have been associated with an increased risk of dementia [7]. Any therapeutic adjustment must be evaluated and personalized by the doctor.

KEY POINTS TO REMEMBER

• Average glucose levels (HbA1c) are associated with the trajectory of cognitive decline in the elderly population; the association also emerges in people without overt diabetes [2].
• Type 2 diabetes is a consolidated risk factor for dementia, with both vascular and metabolic contributions [4][5].
• Neuroimaging studies link higher glycemic levels to reduced volume and altered microstructure of the hippocampus, a critical area for memory [1].
• Episodes of severe hypoglycemia are associated with an increased risk of dementia; therapeutic balance is essential [7].
• Experimental evidence in animal models shows that chronic hyperglycemia can impair neurogenesis and hippocampal function, offering biological plausibility to observational results [8].

Limitations of the evidence

It is essential to distinguish between association and causality. Most relevant research consists of observational studies that can highlight correlations but are subject to the risk of residual confounding (unmeasured factors influencing both glycemia and cognition) and selection bias. Longitudinal cohort studies with repeated measurement of cognitive functions reduce some limitations but do not replace randomized clinical trials to establish a direct causal effect. Variability in definitions (prediabetes, diagnostic criteria for dementia), studied populations (age, cardiovascular background), and measurements (different cognitive tests, different imaging techniques) also contributes to results that are not always comparable [2][3][4].

Finally, pharmacological or nutritional interventions that modify glycemic control can have multiple effects (e.g., on weight, blood pressure, lipids) that make it difficult to attribute any cognitive benefit solely to glucose reduction; studies with robust design and biomarkers are needed to clarify causal relationships and mechanisms [6][3].

Editorial approach and communication recommendations

From an informative point of view, the recommendations to be conveyed to the public are preventive and general: promote the management of cardiovascular and metabolic risk factors, avoid alarmism, and do not propose therapeutic changes not agreed upon with the doctor. Any person with risk factors (obesity, family history, advanced age, cognitive symptoms) should follow clinical guidelines for screening and monitoring, including glycemia and HbA1c checks when indicated. Public health strategies that reduce exposure to obesity and sedentary lifestyles remain the strongest lever at the population level [3][4].

Editorial conclusion

Current evidence indicates a plausible and reproducible relationship between glucose metabolism and brain health: higher blood glucose levels, even if not always beyond the diagnostic threshold for diabetes, are associated with signs of poorer memory function and structural changes in the hippocampus. These associations are supported by biological plausibility and experimental evidence in animal models. However, the observational nature of most data requires caution: we cannot state that interventions aimed exclusively at reducing slight glycemic increases in the non-diabetic population prevent dementia. It remains valid and reasonable to prioritize consolidated metabolic health interventions (physical activity, quality diet, weight control) as part of an overall strategy for the prevention of chronic diseases and, potentially, cognitive loss.

Editorial note

This piece has been updated in light of clinical publications and reference scientific reviews. The cited sources are available in the "Scientific Research" section and include verified DOI links to allow direct consultation of the original articles.

SCIENTIFIC RESEARCH

1. Kerti L, Witte AV, Winkler A, Grittner U, Rujescu D, Flöel A. Higher glucose levels associated with lower memory and reduced hippocampal microstructure. Neurology. 2013;81(20):1746–1752. https://doi.org/10.1212/01.wnl.0000435561.00234.ee
2. Zheng F, Yan L, Yang Z, et al. HbA1c, diabetes and cognitive decline: the English Longitudinal Study of Ageing. Diabetologia. 2018;61(4):839–848. https://doi.org/10.1007/s00125-017-4541-7
3. Biessels GJ, Despa F. Cognitive decline and dementia in diabetes mellitus: mechanisms and clinical implications. Nat Rev Endocrinol. 2018;14(10):591–604. https://doi.org/10.1038/s41574-018-0048-7
4. Gudala K, Bansal D, Schifano F, Bhansali A. Diabetes mellitus and risk of dementia: A meta-analysis of prospective observational studies. J Diabetes Investig. 2013;4(6):640–650. https://doi.org/10.1111/jdi.12087
5. Ahtiluoto S, Polvikoski T, Peltonen M, et al. Diabetes, Alzheimer disease, and vascular dementia: A population-based neuropathologic study. Neurology. 2010;75(13):1195–1202. https://doi.org/10.1212/WNL.0b013e3181f4d7f8
6. Witte AV, Kerti L, Margulies DS, Flöel A. Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults. J Neurosci. 2014;34(23):7862–7870. https://doi.org/10.1523/JNEUROSCI.0385-14.2014
7. Yaffe K, Falvey CM, Hamilton N, et al. Association between hypoglycemia and dementia in a biracial cohort of older adults with diabetes mellitus. JAMA Intern Med. 2013;173(14):1300–1306. https://doi.org/10.1001/jamainternmed.2013.6176
8. Ferreiro E, Lanzillo M, Canhoto D, et al. Chronic hyperglycemia impairs hippocampal neurogenesis and memory in an Alzheimer's disease mouse model. Neurobiol Aging. 2020;92:98–113. https://doi.org/10.1016/j.neurobiolaging.2020.04.003